Lisata Therapeutics (NASDAQ:LSTA) Shares Up 0.4% – Here’s What Happened

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was up 0.4% during trading on Thursday . The company traded as high as $2.79 and last traded at $2.67. Approximately 27,160 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 49,060 shares. The stock had previously closed at $2.66.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on LSTA shares. Zacks Research upgraded Lisata Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 10th. Brookline Capital Management upped their price objective on shares of Lisata Therapeutics from $20.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.50.

Lisata Therapeutics Price Performance

The stock’s fifty day moving average is $2.40 and its 200-day moving average is $2.49. The stock has a market capitalization of $23.39 million, a PE ratio of -1.20 and a beta of 1.04.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The firm had revenue of $0.07 million for the quarter. On average, analysts forecast that Lisata Therapeutics, Inc. will post -2.66 EPS for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,183 shares of the company’s stock, valued at approximately $32,000. Cerity Partners LLC owned approximately 0.14% of Lisata Therapeutics at the end of the most recent quarter. 8.94% of the stock is owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.